Eisai Co.’s Tasurgratinib Study: Key Insights for Investors

Eisai Co ((ESALF)) announced an update on their ongoing clinical study.

Study Overview: Eisai Co. is conducting a study titled An Open-label Parallel-Group Study to Evaluate Pharmacokinetics of E7090 and Its Metabolite in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects. The study aims to assess how mild and moderate hepatic impairment affects the pharmacokinetics of tasurgratinib, a drug administered in a single dose. This research is significant as it could inform dosage adjustments for patients with liver impairments, ensuring safer and more effective treatment.

Intervention/Treatment: The study tests the drug tasurgratinib, administered as either a tablet or capsule. The purpose is to evaluate its pharmacokinetics in individuals with varying degrees of hepatic impairment compared to healthy participants.

Study Design: This Phase 1 interventional study uses a non-randomized, parallel-group model without masking. The primary purpose is treatment-focused, comparing the pharmacokinetics of tasurgratinib across different participant groups.

Study Timeline: The study began on February 13, 2020, and is currently recruiting. The last update was submitted on May 12, 2025. These dates are crucial for tracking the study’s progress and anticipating future updates.

Market Implications: This study’s progress could influence Eisai Co.’s stock performance and investor sentiment, particularly if tasurgratinib shows promise for treating patients with hepatic impairments. The pharmaceutical industry closely watches such developments, as successful outcomes can lead to competitive advantages.

The study is ongoing, with further details available on the ClinicalTrials portal.